Mitral regurgitation at the time of left ventricular assist device implantation: Should it be treated or not?

Hiroki Kohno MD, PhD , Goro Matsumiya MD, PhD , Yoshikatsu Saiki MD, PhD , Koichiro Kinugawa MD, PhD , Minoru Ono MD, PhD
{"title":"Mitral regurgitation at the time of left ventricular assist device implantation: Should it be treated or not?","authors":"Hiroki Kohno MD, PhD ,&nbsp;Goro Matsumiya MD, PhD ,&nbsp;Yoshikatsu Saiki MD, PhD ,&nbsp;Koichiro Kinugawa MD, PhD ,&nbsp;Minoru Ono MD, PhD","doi":"10.1016/j.xjon.2025.02.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Mitral regurgitation may persist or progress after left ventricular assist device implantation. However, whether preexisting mitral regurgitation should be corrected at the time of implantation remains to be determined.</div></div><div><h3>Methods</h3><div>A retrospective, registry-based analysis was performed on 1398 continuous-flow left ventricular assist device recipients who underwent implantation between 2010 and 2022. Patients were compared for significant mitral regurgitation, defined as moderate-to-severe or greater mitral regurgitation after implantation, and major adverse events during left ventricular assist device support. Comparisons were made between patients untreated for mitral regurgitation but who had moderate or greater preexisting mitral regurgitation (n = 414) and those who had no or mild preexisting mitral regurgitation (n = 368) (cohort 1), and between patients with moderate or greater mitral regurgitation who underwent concomitant mitral valve surgery (n = 86) and those who did not (n = 414) (cohort 2).</div></div><div><h3>Results</h3><div>The cumulative incidence of significant mitral regurgitation was higher in patients with untreated moderate or greater mitral regurgitation in both cohorts (<em>P</em> &lt; .001 and <em>P</em> = .025, cohorts 1 and 2, respectively). However, the cumulative incidence of all-cause mortality and readmission, and the risk of other major left ventricular assist device complications such as stroke and right heart failure were comparable between groups in both cohorts. The results were also consistent for the propensity score–matched population created in each cohort.</div></div><div><h3>Conclusions</h3><div>Significant mitral regurgitation may be prevented by concomitant surgery, but late survival and the risk of other major adverse events were not significantly improved by the procedure and were similar between patients with untreated moderate or greater mitral regurgitation and those with no or untreated mild mitral regurgitation. Our results suggest that mitral regurgitation during left ventricular assist device implantation may have only limited benefits from concomitant surgery.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"24 ","pages":"Pages 96-112"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTCVS open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266627362500049X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Mitral regurgitation may persist or progress after left ventricular assist device implantation. However, whether preexisting mitral regurgitation should be corrected at the time of implantation remains to be determined.

Methods

A retrospective, registry-based analysis was performed on 1398 continuous-flow left ventricular assist device recipients who underwent implantation between 2010 and 2022. Patients were compared for significant mitral regurgitation, defined as moderate-to-severe or greater mitral regurgitation after implantation, and major adverse events during left ventricular assist device support. Comparisons were made between patients untreated for mitral regurgitation but who had moderate or greater preexisting mitral regurgitation (n = 414) and those who had no or mild preexisting mitral regurgitation (n = 368) (cohort 1), and between patients with moderate or greater mitral regurgitation who underwent concomitant mitral valve surgery (n = 86) and those who did not (n = 414) (cohort 2).

Results

The cumulative incidence of significant mitral regurgitation was higher in patients with untreated moderate or greater mitral regurgitation in both cohorts (P < .001 and P = .025, cohorts 1 and 2, respectively). However, the cumulative incidence of all-cause mortality and readmission, and the risk of other major left ventricular assist device complications such as stroke and right heart failure were comparable between groups in both cohorts. The results were also consistent for the propensity score–matched population created in each cohort.

Conclusions

Significant mitral regurgitation may be prevented by concomitant surgery, but late survival and the risk of other major adverse events were not significantly improved by the procedure and were similar between patients with untreated moderate or greater mitral regurgitation and those with no or untreated mild mitral regurgitation. Our results suggest that mitral regurgitation during left ventricular assist device implantation may have only limited benefits from concomitant surgery.
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信